NanOlogy, a clinical-stage oncology company, announced the first patient has been enrolled in a clinical trial of NanoDoce (sterile submicron particle docetaxel suspension) for treatment of bladder cancer.
Puma Biotechnology, a biopharmaceutical company, has expanded two additional cohorts from the Phase II SUMMIT clinical trial investigating its lead drug candidate neratinib in patients with solid tumors who have an activating EGFR or HER2 mutation.
ViiV Healthcare today presented three year results from the SWORD 1 & 2 studies, demonstrating that 84% (432/513) of participants who switched from their current three- or four-drug antiretroviral regimen to a 2-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson) maintained viral suppression (viral load ≤50 copies/mL).
Clinical stage biotechnology company QUE Oncology today announces the launch of its Phase II trials which will see its novel non-hormonal therapy, for women with breast cancer suffering hot flashes and night sweats, tested at key sites in the United States.
Sangamo Therapeutics and Pfizer announced interim data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A.
Cellectis has secured approval from the US Food and Drug Administration (FDA) to launch a phase 1 clinical trial for the evaluation of its gene-edited T-cell product candidate UCARTCS1 as a potential treatment for multiple myeloma (MM).
Roche said that ipatasertib, in combination with Tecentriq (atezolizumab) and chemotherapy, demonstrated promising anti-tumor activity in advanced triple-negative breast cancer in a Phase Ib study.
Silence Therapeutics has filed a clinical trial application (CTA) with the UK Medicines and Healthcare products Regulatory Agency (MHRA), seeking approval to launch a phase Ib trial for the investigational drug, SLN124.
UK-based clinical-stage company Evgen Pharma reported that its phase 2 STEM trial evaluating SFX-01 for the treatment of metastatic breast cancer has met its primary endpoints.
Aimmune Therapeutics said that a phase 3 trial held in Europe that evaluated its lead candidate AR101 for the treatment of peanut allergy, met its primary efficacy endpoint.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.